Monoclonal antibody · Antagonist of Programmed death-ligand 1 (CD274) · developed by Emd Serono
Avelumab is a human IgG1 monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1 and B7.1 on T cells and antigen-presenting cells, restoring anti-tumor immune responses. It also induces antibody-dependent cell-mediated cytotoxicity against PD-L1-expressing cells. It is studied in epithelial ovarian cancer and non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03169790 | Phase 1/2 | Non Hodgkin Lymphoma | Withdrawn | IBRX |
| NCT02943317 | Phase 1 | Epithelial Ovarian Cancer | Terminated | VSTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Epithelial Ovarian CancerNon Hodgkin Lymphoma
Updated Nov 15, 2026.